Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 12)
|
BridgeBio Pharma, Inc. (Name of Issuer) |
Common Stock, par value $0.001 per share (Title of Class of Securities) |
10806X102 (CUSIP Number) |
Matthew Bloom
General Counsel, 600 Washington Boulevard, Floor 11
Stamford, CT, 06901
(212) 672-7059
General Counsel, 600 Washington Boulevard, Floor 11
Stamford, CT, 06901
(212) 672-7059
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
07/09/2026
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
VIKING GLOBAL INVESTORS LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Common Stock, par value $0.001 per share (the "Common Stock"), of BridgeBio Pharma, Inc. (the "Issuer"). The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
All share percentage calculations in this Amendment No. 12 to the Schedule 13D are based on 196,036,786 shares of Common Stock of the Issuer outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the Securities and Exchange Commission (the "Commission") on July 2, 2026.
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
Viking Global Opportunities Parent GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
Viking Global Opportunities GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
Viking Global Opportunities Portfolio GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
Viking Global Opportunities Illiquid Investments Sub-Master LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CAYMAN ISLANDS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
HALVORSEN OLE ANDREAS | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
NORWAY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
SCHEDULE 13D
|
| CUSIP Number(s): | 10806X102 |
| 1 |
Name of reporting person
Shabet Rose Sharon | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
9,792,219.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.001 per share | |
| (b) | Name of Issuer:
BridgeBio Pharma, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
3160 Porter Drive, Suite 250, Palo Alto,
CALIFORNIA
, 94304. | |
Item 1 Comment:
Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 12 to the Schedule 13D ("Amendment No. 12") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024, Amendment No. 4 filed with the Commission on November 6, 2024, Amendment No. 5 filed with the Commission on January 31, 2025, Amendment No. 6 filed with the Commission on March 12, 2025, Amendment No. 7 filed with the Commission on July 1, 2025, Amendment No. 8 filed with the Commission on August 14, 2025, Amendment No. 9 filed with the Commission on November 14, 2025, Amendment No. 10 filed with the Commission on February 17, 2026 and Amendment No. 11 filed with the Commission on April 2, 2026 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. | ||
| Item 4. | Purpose of Transaction | |
Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
The response to Item 5(c) of this Amendment No. 12 is incorporated by reference herein. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows:
The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference.
Each of the Reporting Persons beneficially owns approximately 4.9951% of the outstanding shares of the Issuer's Common Stock. The percent of class reported in Row 13 of each Reporting Person's cover sheet has been rounded to 5% in accordance with the instructions to Schedule 13D in Rule 13d-101. Such percentage was calculated for each Reporting Person based on 196,036,786 shares of Common Stock outstanding as of May 31, 2026, as reported in exhibit 10.1 to the Issuer's current report on Form 8-K filed with the Commission on July 2, 2026.
Opportunities Fund has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to Opportunities Fund. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through Opportunities Fund.
VGI provides managerial services to Opportunities Fund. VGI has the power to direct the voting and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, VGI may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund.
Opportunities Portfolio GP serves as the general partner of Opportunities Fund and has the power to direct the voting and disposition of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Portfolio GP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund.
Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the power to direct the voting and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities GP may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities Portfolio GP, consisting of any shares of Common Stock directly owned by Opportunities Fund.
Opportunities Parent serves as the sole member of Opportunities GP, which has the power to direct the voting and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund. Accordingly, Opportunities Parent may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities GP, consisting of any shares of Common Stock directly owned by Opportunities Fund.
Mr. Halvorsen and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (the general partner of VGI) and Opportunities Parent, have shared authority to direct the voting and disposition of the shares of Common Stock beneficially owned by VGI and Opportunities Parent. Accordingly, each of Mr. Halvorsen and Ms. Shabet may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by VGI and Opportunities Parent.
Except as disclosed in this Amendment No. 12, none of the Reporting Persons beneficially owns any shares of Common Stock or has the right to acquire any shares of Common Stock.
Except as disclosed in this Amendment No. 12, none of the Reporting Persons presently has the power to vote or to direct the voting or to dispose or direct the disposition of any shares of Common Stock that such Reporting Person may be deemed to beneficially own. | |
| (b) | Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows:
The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference. | |
| (c) | Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows:
Except for the transactions listed in Exhibit 99.14 of this Amendment No. 12, the Reporting Persons have not effected any transactions in the Common Stock during the past 60 days. | |
| (e) | As of July 9, 2026, the Reporting Persons ceased to be beneficial owners of more than 5% of the shares of Common Stock. | |
| Item 7. | Material to be Filed as Exhibits. | |
Item 7 of the Schedule 13D is hereby amended and supplemented as follows:
Exhibit 99.14 - Schedule of Transactions | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comments accompanying signature:
(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
(2) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). |